Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01741753
Title BKM120+Abiraterone Acetate for Metastatic CRPC
Recruitment Terminated
Gender male
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute

prostate cancer


Abiraterone + Buparlisib + Prednisone

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Beth-Israel Deaconess Medical Center Boston Massachusetts 02115 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02115 United States Details
*Shaded cells indicate that there was no data available from for the field